# Clinical trial results:
# A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease

## Summary

| | |
|---|---|
| EudraCT number | 2007-005839-28 |
| Trial protocol | SE ES HU FR AT FI NL DE |
| Global end of trial date | 23 November 2017 |

### Results information

| | |
|---|---|
| Result version number | v2 (current) |
| This version publication date | 26 December 2018 |
| First version publication date | 15 April 2017 |
| Version creation reason | |

## Trial information

### Trial identification

| | |
|---|---|
| Sponsor protocol code | 0859-019 |

### Additional study identifiers

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT00685776 |
| WHO universal trial number (UTN) | - |

Notes:

### Sponsors

| | |
|---|---|
| Sponsor organisation name | Merck Sharp & Dohme Corp. |
| Sponsor organisation address | 2000 Galloping Hill Road, Kenilworth, United States, 07033 |
| Public contact | Clinical Trials Disclosure, Merck Sharp and Dohme Corp., ClinicalTrialsDisclosure@merck.com |
| Scientific contact | Clinical Trials Disclosure, Merck Sharp and Dohme Corp., ClinicalTrialsDisclosure@merck.com |

Notes:

### Paediatric regulatory details

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 01 July 2009 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 23 November 2017 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

This study evaluated the efficacy of anacetrapib 100 mg for 24 weeks relative to placebo, on plasma concentrations of Low Density Lipoprotein Cholesterol and assessed the 76-week safety and tolerability of anacetrapib 100mg in participants with coronary heart disease (CHD)/CHD risk equivalent disease on stable dose regimen of statin with or without other lipid-modifying therapy. The 2 year extension to this study further evaluated the long-term safety profile and efficacy of anacetrapib 100 mg in CHD/CHD-risk equivalent participants who were on ongoing therapy with a statin with or without other lipid-modifying therapy.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy:

All participants were required to be on a stable-regimen of statin ± other lipid-modifying medication(s) for at least 6-weeks prior to enrollment.

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 24 March 2008 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Australia: 59 |
| Country: Number of subjects enrolled | Austria: 34 |
| Country: Number of subjects enrolled | Canada: 62 |
| Country: Number of subjects enrolled | Colombia: 5 |
| Country: Number of subjects enrolled | Finland: 51 |
| Country: Number of subjects enrolled | France: 38 |
| Country: Number of subjects enrolled | Germany: 42 |
| Country: Number of subjects enrolled | Hong Kong: 36 |
| Country: Number of subjects enrolled | Hungary: 82 |
| Country: Number of subjects enrolled | Israel: 59 |
| Country: Number of subjects enrolled | Malaysia: 66 |
| Country: Number of subjects enrolled | Mexico: 68 |
| Country: Number of subjects enrolled | Netherlands: 186 |
| Country: Number of subjects enrolled | New Zealand: 48 |
| Country: Number of subjects enrolled | Norway: 48 |

| | |
|---|---|
| Country: Number of subjects enrolled | Peru: 35 |
| Country: Number of subjects enrolled | Russian Federation: 47 |
| Country: Number of subjects enrolled | Spain: 93 |
| Country: Number of subjects enrolled | Sweden: 74 |
| Country: Number of subjects enrolled | United States: 490 |
| Worldwide total number of subjects | 1623 |
| EEA total number of subjects | 648 |

Notes:

| **Subjects enrolled per age group** | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 889 |
| From 65 to 84 years | 734 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

Base study consisted of a 76 week treatment period and a 12-week reversal period (no treatment). The active study was extended for 2-years which was followed by a 1 year reversal (no treatment).

### Pre-assignment

Screening details:

This study was enrolled participants with coronary heart disease (CHD) or CHD risk-equivalent disease that were taking a statin with or without other lipid-modifying medications. Other inclusion and exclusion criteria applied.

### Period 1

| | |
|---|---|
| Period 1 title | Base Study - Treatment Phase (Part A) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Anacetrapib |

Arm description:

one 100-mg Anacetrapib tablet daily with food for 76 weeks administered with participant's current stable regimen of lipid-lowering therapy.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Anacetrapib |
| Investigational medicinal product code | |
| Other name | MK-0859 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

one 100-mg tablet once daily

| | |
|---|---|
| **Arm title** | Placebo |

Arm description:

one placebo tablet daily with food for 76 weeks administered with participant's current stable regimen of lipid-lowering therapy.

| | |
|---|---|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

one 100-mg tablet once daily

| **Number of subjects in period 1** | Anacetrapib | Placebo |
|---|---|---|
| Started | 811 | 812 |
| Completed | 548 | 663 |
| Not completed | 263 | 149 |
| Physician decision | 6 | 6 |
| Consent withdrawn by subject | 46 | 57 |
| Adverse Event | 46 | 48 |
| LDL-C Stopping Criteria Met | 142 | 1 |
| Study Terminated by Sponsor | 5 | 3 |
| Lost to follow-up | 3 | 13 |
| Lack of efficacy | 1 | 1 |
| Protocol deviation | 14 | 20 |

## Period 2

| | |
|---|---|
| Period 2 title | Base Study - Reversal (Part B) |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor |

## Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Anacetrapib 100 mg - Base Study Reversal |

Arm description:

Completers and Non-completers who received 100 mg Anacetrapib during treatment period. Participants continue with current stable regimen of lipid-lowering therapy.

| | |
|---|---|
| Arm type | No intervention |

No investigational medicinal product assigned in this arm

| | |
|---|---|
| **Arm title** | Placebo -Base Study Reversal |

Arm description:

Completers and non-completers who received placebo in treatment period of base study. Participants continue with current stable regimen of lipid-lowering therapy.

| | |
|---|---|
| Arm type | No intervention |

No investigational medicinal product assigned in this arm

| Number of subjects in period 2 | Anacetrapib 100 mg - Base Study Reversal | Placebo -Base Study Reversal |
|---|---|---|
| Started | 548 | 663 |
| Completed | 655 | 690 |
| Not completed | 29 | 24 |
| Unknown | 29 | 24 |
| Joined | 136 | 51 |
| non-completers from treatment phase | 136 | 51 |

## Period 3

| | |
|---|---|
| Period 3 title | 2-year Extension (Part C) |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | No |
| **Arm title** | Anacetrapib-Extension Study |

Arm description:

one 100-mg Anacetrapib tablet daily with food for 104 weeks administered with participant's current stable regimen of lipid-lowering therapy.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Anacetrapib |
| Investigational medicinal product code | |
| Other name | MK-0859 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

one 100-mg tablet once daily

| | |
|---|---|
| **Arm title** | Placebo-Extension Study |

Arm description:

one placebo tablet daily with food for 104 weeks administered with participant's current stable regimen of lipid-lowering therapy.

| | |
|---|---|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

one 100-mg tablet once daily

| Number of subjects in period 3 | Anacetrapib-Extension Study | Placebo-Extension Study |
|---|---|---|
| Started | 370 | 433 |
| Completed | 328 | 386 |
| Not completed | 42 | 47 |
| Physician decision | 2 | 4 |
| Consent withdrawn by subject | 17 | 18 |
| Adverse event, non-fatal | 18 | 23 |
| Lost to follow-up | 1 | 1 |
| Protocol deviation | 4 | - |
| Lack of efficacy | - | 1 |

**Period 4**

| | |
|---|---|
| Period 4 title | 1-year Reversal (Part D) |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor |

**Arms**

| | |
|---|---|
| Are arms mutually exclusive? | No |
| **Arm title** | Anacetrapib-1 year Reversal Study |

Arm description:

Participants who received Anacetrapib 100 mg in Extension (Part C). Participants continue with current stable regimen of lipid-lowering therapy.

| | |
|---|---|
| Arm type | No intervention |

No investigational medicinal product assigned in this arm

| | |
|---|---|
| **Arm title** | Placebo-1 year Reversal Study |

Arm description:

Participants who received placebo in Extension (Part C). Participants continue with current stable regimen of lipid-lowering therapy.

| | |
|---|---|
| Arm type | No intervention |

No investigational medicinal product assigned in this arm

| Number of subjects in period 4 | Anacetrapib-1 year Reversal Study | Placebo-1 year Reversal Study |
|---|---|---|
| Started | 271 | 1 |
| Completed | 266 | 1 |
| Not completed | 5 | 0 |
| Physician decision | 1 | - |
| Consent withdrawn by subject | 1 | - |

| | | |
|---|---|---|
| Adverse event, non-fatal | 1 | - |
| Lost to follow-up | 1 | - |
| Progressive disease | 1 | - |

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | Anacetrapib |
| Reporting group description: | |
| one 100-mg Anacetrapib tablet daily with food for 76 weeks administered with participant's current stable regimen of lipid-lowering therapy. | |
| Reporting group title | Placebo |
| Reporting group description: | |
| one placebo tablet daily with food for 76 weeks administered with participant's current stable regimen of lipid-lowering therapy. | |

| Reporting group values | Anacetrapib | Placebo | Total |
|---|---|---|---|
| Number of subjects | 811 | 812 | 1623 |
| Age Categorical<br>Units: Subjects | | | |
| Age Continuous<br>Units: years | | | |
| arithmetic mean | 62.5 | 62.9 | |
| standard deviation | ± 8.7 | ± 9 | - |
| Gender Categorical<br>Units: Subjects | | | |
| Female | 182 | 194 | 376 |
| Male | 629 | 618 | 1247 |

## End points

### End points reporting groups

| | |
|---|---|
| Reporting group title | Anacetrapib |
| Reporting group description: | |
| one 100-mg Anacetrapib tablet daily with food for 76 weeks administered with participant's current stable regimen of lipid-lowering therapy. | |
| Reporting group title | Placebo |
| Reporting group description: | |
| one placebo tablet daily with food for 76 weeks administered with participant's current stable regimen of lipid-lowering therapy. | |
| Reporting group title | Anacetrapib 100 mg - Base Study Reversal |
| Reporting group description: | |
| Completers and Non-completers who received 100 mg Anacetrapib during treatment period. Participants continue with current stable regimen of lipid-lowering therapy. | |
| Reporting group title | Placebo -Base Study Reversal |
| Reporting group description: | |
| Completers and non-completers who received placebo in treatment period of base study. Participants continue with current stable regimen of lipid-lowering therapy. | |
| Reporting group title | Anacetrapib-Extension Study |
| Reporting group description: | |
| one 100-mg Anacetrapib tablet daily with food for 104 weeks administered with participant's current stable regimen of lipid-lowering therapy. | |
| Reporting group title | Placebo-Extension Study |
| Reporting group description: | |
| one placebo tablet daily with food for 104 weeks administered with participant's current stable regimen of lipid-lowering therapy. | |
| Reporting group title | Anacetrapib-1 year Reversal Study |
| Reporting group description: | |
| Participants who received Anacetrapib 100 mg in Extension (Part C). Participants continue with current stable regimen of lipid-lowering therapy. | |
| Reporting group title | Placebo-1 year Reversal Study |
| Reporting group description: | |
| Participants who received placebo in Extension (Part C). Participants continue with current stable regimen of lipid-lowering therapy. | |
| Subject analysis set title | Anacetrapib 100 mg - Base Study- Efficacy |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | |
| All randomized participants who were not excluded due to failure to receive at least 1 dose of study treatment, lack of any post-randomization endpoint data subsequent to at least 1 dose of study treatment or lacked baseline data for those analyses that required baseline data. | |
| Subject analysis set title | Placebo - Base Study - Efficacy |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | |
| All randomized participants who were not excluded due to failure to receive at least 1 dose of study treatment, lack of any post-randomization endpoint data subsequent to at least 1 dose of study treatment or lack, of baseline data for those analyses that require baseline data. | |
| Subject analysis set title | Anacetrapib 100 mg - Base Study - Safety |
| Subject analysis set type | Safety analysis |
| Subject analysis set description: | |
| All randomized participants who received at least 1 dose of study treatment in Base Study and had at least 1 post-baseline measurement for parameter assessed. | |
| Subject analysis set title | Placebo - Base Study- Safety |
| Subject analysis set type | Safety analysis |

Subject analysis set description:

All randomized participants who received at least 1 dose of study treatment in Base Study and has at least 1 post-baseline measurement for parameter assessed.

| | |
|---|---|
| Subject analysis set title | Anacetrapib 100 mg - Extension Study - Efficacy |
| Subject analysis set type | Full analysis |

Subject analysis set description:

All randomized participants who were not excluded due to failure to receive at least 1 dose of study treatment, lack of any post-randomization endpoint data subsequent to at least 1 dose of study treatment or lack of baseline data for those analyses that required baseline data.

| | |
|---|---|
| Subject analysis set title | Placebo- Extension Study - Efficacy |
| Subject analysis set type | Full analysis |

Subject analysis set description:

All randomized participants who were not excluded due to failure to receive at least 1 dose of study treatment, lack of any post-randomization endpoint data subsequent to at least 1 dose of study treatment, or lack of baseline data for those analyses that required baseline data.

| | |
|---|---|
| Subject analysis set title | Anacetrapib 100 mg -Extension-Safety |
| Subject analysis set type | Safety analysis |

Subject analysis set description:

All randomized participants who received at least 1 dose of study treatment in extension and had at least 1 post-baseline measurement for parameter assessed.

| | |
|---|---|
| Subject analysis set title | Placebo-Extension Study-Safety |
| Subject analysis set type | Safety analysis |

Subject analysis set description:

All randomized participants who received at least 1 dose of study treatment in Extension Study and had at least 1 post-baseline measurement for parameter assessed.

| | |
|---|---|
| Subject analysis set title | Anacetrapib-1 year Reversal Study-Safety |
| Subject analysis set type | Safety analysis |

Subject analysis set description:

Participants who received Anacetrapib 100 mg in Extension (Part C) and had available safety data

| | |
|---|---|
| Subject analysis set title | Placebo-1 year Reversal Study-Safety |
| Subject analysis set type | Safety analysis |

Subject analysis set description:

Participants who received placebo in Extension (Part C) and had available safety data

## Primary: Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24- Base Study

| | |
|---|---|
| End point title | Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24- Base Study |

End point description:

LDL-C levels measured at baseline and after 24 weeks of treatment measured by Friedewald method

| | |
|---|---|
| End point type | Primary |

End point timeframe:

Baseline and Week 24

| **End point values** | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 682 | 742 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | -44.6 (-46.3 to -42.8) | -4.5 (-6.2 to -2.8) | | |

## Statistical analyses

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |
| Number of subjects included in analysis | 1424 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.001 |
| Method | Constrained Longitudinal Data Analysis; |
| Parameter estimate | Difference in Least squares (LS) means |
| Point estimate | -40.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -42.4 |
| upper limit | -37.7 |

## Primary: Number of Participants With Hepatitis-related Adverse Events (AEs)- Base Study

| End point title | Number of Participants With Hepatitis-related Adverse Events (AEs)- Base Study[1] |
|---|---|

End point description:

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Hepatitis-related AEs were identified by a collective review using the following prespecified set of preferred terms: cholestasis, hepatic necrosis, hepatocellular damage, cytolytic hepatitis, hepatitis, hepatomegaly, jaundice, hepatic failure, hepatitis cholestatic, jaundice cholestatic, hepatitis fulminant, hyperbilirubinaemia, jaundice hepatocellular, ocular icterus, yellow skin, hepatic function abnormal, acute hepatic failure, subacute hepatic failure, hepatitis acute, hepatitis toxic, hepatotoxicity, and mixed hepatocellular-cholestatic injury.

| End point type | Primary |
|---|---|

End point timeframe:

up to 88 weeks

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical comparisons were planned for this endpoint.

| End point values | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 808 | 804 | | |
| Units: Participants | 1 | 1 | | |

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Participants with Alanine Aminotransferase and/or Aspartate Aminotransferase Consecutive Elevations ≥ 3xULN (Upper Limit of Normal)- Treatment Phase-Base Study

| End point title | Percentage of Participants with Alanine Aminotransferase and/or Aspartate Aminotransferase Consecutive Elevations ≥ 3xULN (Upper Limit of Normal)- Treatment Phase-Base Study |
|---|---|

End point description:

Participants had alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels assessed throughout the 76 week Treatment Phase. Participants who had 2 consecutive assessments of ALT and/or AST that were 3 x ULN or greater were recorded. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively.

| End point type | Primary |
|---|---|

End point timeframe:

up to 76 weeks

| End point values | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 800 | 796 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 0.1 | 1 | | |

### Statistical analyses

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1596 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.019 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | -0.9 |

| | |
|---|---|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.9 |
| upper limit | -0.2 |

## Primary: Percentage of Participants with Creatine Phosphokinase Elevations ≥10 x ULN- Treatment Phase-Base Study

| | |
|---|---|
| End point title | Percentage of Participants with Creatine Phosphokinase Elevations ≥10 x ULN- Treatment Phase-Base Study |

End point description:

Participants had creatine phosphokinase (CK) levels assessed throughout the 76 week Treatment Phase. Participants who had any CK level that was ≥ 10 x ULN were recorded. The ULNs for males and females were 207 IU/L and 169 IU/L, respectively.

| | |
|---|---|
| End point type | Primary |

End point timeframe:

up to 76 weeks

| End point values | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 800 | 796 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 0 | 0.3 | | |

### Statistical analyses

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1596 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.156 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | -0.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.9 |
| upper limit | 0.2 |

## Primary: Percentage of Participants with Creatine Phosphokinase Elevations ≥10 x ULN with Muscle Symptoms- Treatment Phase-Base Study

| | |
|---|---|
| End point title | Percentage of Participants with Creatine Phosphokinase Elevations ≥10 x ULN with Muscle Symptoms- Treatment Phase-Base Study |

End point description:

Participants had CK levels assessed throughout the 76 week Treatment Phase. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The ULNs for males and females were 207 IU/L and 169 IU/L, respectively.

| | |
|---|---|
| End point type | Primary |

End point timeframe:

up to 76 weeks

| End point values | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 800 | 796 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 0 | 0 | | |

### Statistical analyses

| Statistical analysis title | Comparison Between Groups |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1596 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | > 0.999 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.5 |
| upper limit | 0.5 |

## Primary: Percentage of Participants with Sodium, Chloride, or Bicarbonate Elevations >ULN-Treatment Phase- Base Study

| | |
|---|---|
| End point title | Percentage of Participants with Sodium, Chloride, or Bicarbonate Elevations >ULN-Treatment Phase- Base Study |

End point description:

Participants had sodium, chloride, and bicarbonate levels assessed throughout the 76 week Treatment Phase. Participants who had any sodium level that was > the ULN of 145 mEq/L had any chloride level that was > the ULN of 110 mEq/L or had any bicarbonate level that was > the ULN of 33 mEq/L were

recorded

| | |
|---|---|
| End point type | Primary |
| End point timeframe: | |
| up to 76 weeks | |

| **End point values** | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 800 | 796 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | | | | |
| Sodium | 13.9 | 12.9 | | |
| Chloride | 3.9 | 4.4 | | |
| Bicarbonate | 1.5 | 2.1 | | |

**Statistical analyses**

| **Statistical analysis title** | Comparison Between Groups - Sodium |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1596 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.584 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | 0.9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.4 |
| upper limit | 4.3 |

| **Statistical analysis title** | Between Group Comparison- Chloride |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1596 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.601 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | -0.5 |

| | |
|---|---|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.5 |
| upper limit | 1.5 |

| | |
|---|---|
| **Statistical analysis title** | Between Group Comparison - Bicarbonate |
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1596 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.342 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | -0.6 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.1 |
| upper limit | 0.7 |

**Primary: Percentage of Participants with Potassium Levels <LLN (Lower Limit of Normal)- Treatment Phase- Base Study**

| | |
|---|---|
| End point title | Percentage of Participants with Potassium Levels <LLN (Lower Limit of Normal)- Treatment Phase- Base Study |

End point description:

Participants had potassium levels assessed throughout the 76 week Treatment Phase. Participants who had any potassium level that was < the LLN of 3.5 mEq/L were recorded.

| | |
|---|---|
| End point type | Primary |

End point timeframe:

up to 76 weeks

| **End point values** | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 800 | 796 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 5 | 4.6 | | |

**Statistical analyses**

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1596 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.743 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | 0.4 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.8 |
| upper limit | 2.5 |

| **Primary: Percentage of Participants with Myalgia- Treatment Phase- Base Study** | |
|---|---|
| End point title | Percentage of Participants with Myalgia- Treatment Phase- Base Study |
| End point description: | |
| Adverse events were recorded throughout the 76 week Treatment Phase. The percentage of participants who experienced an AE reported with verbatim term "myalgia" were summarized. | |
| End point type | Primary |
| End point timeframe: | |
| up to 76 weeks | |

| **End point values** | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 808 | 804 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 4 | 3.5 | | |

**Statistical analyses**

| **Statistical analysis title** | Comparison Between Groups |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |

| | |
|---|---|
| Number of subjects included in analysis | 1612 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.612 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | 0.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.4 |
| upper limit | 2.4 |

## Primary: Percentage of Participants with Rhabdomyolysis- Treatment Phase- Base Study

| | |
|---|---|
| End point title | Percentage of Participants with Rhabdomyolysis- Treatment Phase- Base Study |

End point description:

Adverse events were recorded throughout the 76 week Treatment Phase. The percentage of participants who experienced an AE reported with verbatim term "rhabdomyolysis" were summarized.

| | |
|---|---|
| End point type | Primary |

End point timeframe:

up to 76 weeks

| End point values | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 808 | 804 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 0 | 0 | | |

### Statistical analyses

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1612 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | > 0.999 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | 0 |

| | |
|---|---|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.5 |
| upper limit | 0.5 |

## Primary: Percentage of Participants with Prespecified Adjudicated Cardiovascular Serious Adverse Events (SAEs)- Treatment Phase- Base Study

| | |
|---|---|
| End point title | Percentage of Participants with Prespecified Adjudicated Cardiovascular Serious Adverse Events (SAEs)- Treatment Phase- Base Study |

End point description:

Participants who experienced the SAEs of CV death, Non-fatal stroke, non-fatal myocardial infarction, or unstable angina during the 76 week Treatment Phase were recorded. These cardiovascular events that occurred during the Base Study were adjudicated by an expert committee external to the sponsor.

| | |
|---|---|
| End point type | Primary |

End point timeframe:

up to 76 weeks

| End point values | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 808 | 804 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 1.6 | 2.6 | | |

### Statistical analyses

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1612 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.161 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | -1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.4 |
| upper limit | 0.4 |

## Primary: Percentage of Participants with Death from Any Cause- Treatment Phase- Base Study

| End point title | Percentage of Participants with Death from Any Cause- Treatment Phase- Base Study |
|---|---|

End point description:

Participants who died from any cause during the 76 week Treatment Phase were recorded. All deaths were adjudicated by an expert committee independent of the Sponsor.

| End point type | Primary |
|---|---|

End point timeframe:

up to 76 weeks

| End point values | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 808 | 804 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 0.7 | 0.9 | | |

### Statistical analyses

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1612 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.774 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | -0.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.1 |
| upper limit | 0.8 |

## Primary: Percentage of Participants with Alanine Aminotransferase and/or Aspartate Aminotransferase Consecutive Elevations ≥ 3xULN (Upper Limit of Normal)- Extension Study

| End point title | Percentage of Participants with Alanine Aminotransferase and/or Aspartate Aminotransferase Consecutive Elevations ≥ 3xULN (Upper Limit of Normal)- Extension Study |
|---|---|

End point description:

Participants had alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels assessed throughout the 104 week Extension Study. Participants who had 2 consecutive assessments of ALT and/or AST that were 3 x ULN or greater were recorded. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively.

| End point type | Primary |
|---|---|

End point timeframe:

up to 104 weeks

| **End point values** | Anacetrapib 100 mg - Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 366 | 433 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 0.3 | 0.9 | | |

**Statistical analyses**

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 799 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Percentages |
| Point estimate | -0.7 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.1 |
| upper limit | 0.7 |

## Primary: Percentage of Participants with Creatine Phosphokinase Elevations ≥10xULN- Extension Study

| End point title | Percentage of Participants with Creatine Phosphokinase Elevations ≥10xULN- Extension Study |
|---|---|

End point description:

Participants had creatine phosphokinase (CK) levels assessed throughout the 104 week Extension Study. Participants who had any CK level that was >=10 x ULN were recorded. The ULNs for males and females were 207 IU/L and 169 IU/L, respectively.

| End point type | Primary |
|---|---|

End point timeframe:

up to 104 weeks

| End point values | Anacetrapib 100 mg - Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 366 | 433 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 0 | 0 | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 799 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Percentages |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.9 |
| upper limit | 1 |

**Primary: Percentage of Participants with Creatine Phosphokinase Elevations ≥10xULN with Muscle Symptoms- Extension Study**

| End point title | Percentage of Participants with Creatine Phosphokinase Elevations ≥10xULN with Muscle Symptoms- Extension Study |
|---|---|

End point description:

Participants had CK levels assessed throughout the 104 week Extension Study. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The ULNs for males and females were 207 IU/L and 169 IU/L, respectively.

| End point type | Primary |
|---|---|

End point timeframe:

up to 104 weeks

| End point values | Anacetrapib 100 mg - Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 366 | 433 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 0 | 0 | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 799 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Percentages |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.9 |
| upper limit | 1 |

**Primary: Percentage of Participants with Sodium, Chloride, or Bicarbonate Elevations >ULN- Extension Study**

| End point title | Percentage of Participants with Sodium, Chloride, or Bicarbonate Elevations >ULN- Extension Study |
|---|---|

End point description:

Participants had sodium, chloride, and bicarbonate levels assessed throughout the 104 week Extension Study. Participants who had any sodium level that was > the ULN of 145 mEq/L had any chloride level that was > the ULN of 110 mEq/L or had any bicarbonate level that was > the ULN of 33 mEq/L were recorded

| End point type | Primary |
|---|---|

End point timeframe:

up to 104 weeks

| End point values | Anacetrapib 100 mg - Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 366 | 433 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | | | | |
| Sodium | 7.1 | 5.3 | | |

| | | | | |
|---|---|---|---|---|
| Chloride | 1.4 | 0.5 | | |
| Bicarbonate | 1.4 | 1.4 | | |

**Statistical analyses**

| **Statistical analysis title** | Between Group Comparison- Sodium |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 799 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Percentages |
| Point estimate | 1.8 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.6 |
| upper limit | 5.4 |

| **Statistical analysis title** | Between Group Comparison- Bicarbonate |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 799 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Percentages |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.8 |
| upper limit | 1.9 |

| **Statistical analysis title** | Between Group Comparison- Chloride |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 799 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Percentages |
| Point estimate | 0.9 |

| | |
|---|---|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.5 |
| upper limit | 2.7 |

## Primary: Percentage of Participants with Potassium Levels <LLN (Lower Limit of Normal)- Extension Study

| | |
|---|---|
| End point title | Percentage of Participants with Potassium Levels <LLN (Lower Limit of Normal)- Extension Study |

End point description:

Participants had potassium levels assessed throughout the 104 week Extension Study. Participants who had any potassium level that was < the LLN of 3.5 mEq/L were recorded.

| | |
|---|---|
| End point type | Primary |

End point timeframe:

up to 104 weeks

| **End point values** | Anacetrapib 100 mg -Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 366 | 432 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 2.2 | 3 | | |

### Statistical analyses

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 798 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Percentages |
| Point estimate | -0.8 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.2 |
| upper limit | 1.6 |

## Primary: Percentage of Participants with Myalgia- Extension Study

| End point title | Percentage of Participants with Myalgia- Extension Study |
|---|---|

End point description:

Adverse events were recorded throughout the 104 week Extension Study. The number of participants who experienced an AE reported with verbatim term "myalgia" were summarized.

| End point type | Primary |
|---|---|

End point timeframe:

up to 104 weeks

| **End point values** | Anacetrapib 100 mg -Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 369 | 433 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 1.6 | 2.5 | | |

**Statistical analyses**

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 802 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.371 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | -0.9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.1 |
| upper limit | 1.2 |

**Primary: Percentage of Participants with Rhabdomyolysis- Extension Study**

| End point title | Percentage of Participants with Rhabdomyolysis- Extension Study |
|---|---|

End point description:

Adverse events were recorded throughout the 104 week Extension Study. The number of participants who experienced an AE reported with verbatim term "rhabdomyolysis" were summarized.

| End point type | Primary |
|---|---|

End point timeframe:

up to 104 weeks

| End point values | Anacetrapib 100 mg - Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 369 | 433 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 0 | 0.2 | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 802 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.356 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | -0.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.3 |
| upper limit | 0.8 |

**Primary: Percentage of Participants with Prespecified Adjudicated Cardiovascular Serious Adverse Events (SAEs)- Extension Study**

| End point title | Percentage of Participants with Prespecified Adjudicated Cardiovascular Serious Adverse Events (SAEs)- Extension Study |
|---|---|

End point description:

Participants who experienced the SAEs of cardiovascular (CV) death, Non-fatal stroke, non-fatal myocardial infarction, or unstable angina during the 104 week Extension Study were recorded. These cardiovascular events that occurred during the Base Study were adjudicated by an expert committee external to the sponsor.

| End point type | Primary |
|---|---|

End point timeframe:

up to 104 weeks

| End point values | Anacetrapib 100 mg - Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 370 | 433 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 3.8 | 3.2 | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 803 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Percentages |
| Point estimate | 0.6 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.1 |
| upper limit | 3.3 |

**Primary: Percentage of Participants with Death from Any Cause- Extension Study**

| End point title | Percentage of Participants with Death from Any Cause-Extension Study |
|---|---|

End point description:

Participants who died from any cause during the 104 week Extension Study were recorded. All deaths were adjudicated by an expert committee independent of the Sponsor.

| End point type | Primary |
|---|---|

End point timeframe:

up to 104 weeks

| End point values | Anacetrapib 100 mg - Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 370 | 433 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 2.4 | 2.1 | | |

## Statistical analyses

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 803 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Percentages |
| Point estimate | 0.4 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.8 |
| upper limit | 2.7 |

## Primary: Percentage of Participants Who Experience at Least 1 AE- 1 year Reversal Study

| End point title | Percentage of Participants Who Experience at Least 1 AE- 1 year Reversal Study[2] |
|---|---|

End point description:

An AE was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. Note: An interactive voice response system (IVRS) distribution error resulted in only 1 participant who received placebo during the 2-year extension enrolled in the 1-year reversal phase instead of the approximately 68 placebo participants that were planned. All participants who had received anacetrapib 100 mg during the 2 year extension enrolled as planned in the 1-year reversal phase. Thus no comparative analysis was performed on data from the 1-year reversal phase.

| End point type | Primary |
|---|---|

End point timeframe:

up to 52 weeks

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical comparisons were planned for this endpoint.

| End point values | Anacetrapib-1 year Reversal Study-Safety | Placebo-1 year Reversal Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 271 | 1 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 49.4 | 0.0 | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Participants Who Experience at Least 1 Drug-related AE- 1

## year Reversal Study

| End point title | Percentage of Participants Who Experience at Least 1 Drug-related AE- 1 year Reversal Study[3] |
|---|---|

End point description:

An AE was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. Adverse events reported as at least possibly related to study drug were summarized. Note: An IVRS distribution error resulted in only 1 participant who received placebo during the 2-year extension enrolled in the 1-year reversal phase instead of the approximately 68 placebo participants that were planned. All participants who had received anacetrapib 100 mg during the 2 year extension enrolled as planned in the 1-year reversal phase. Thus no comparative analysis was performed on data from the 1-year reversal phase.

| End point type | Primary |
|---|---|

End point timeframe:

up to 52 weeks

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical comparisons were planned for this endpoint.

| **End point values** | Anacetrapib-1 year Reversal Study-Safety | Placebo-1 year Reversal Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 271 | 1 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 1.5 | 0.0 | | |

### Statistical analyses

No statistical analyses for this end point

## Primary: Change From Baseline in Sodium at Week 76-Base Study

| End point title | Change From Baseline in Sodium at Week 76-Base Study |
|---|---|

End point description:

Sodium levels were assessed at baseline and after 76 weeks of treatment. The change from baseline was recorded.

| End point type | Primary |
|---|---|

End point timeframe:

Baseline and Week 76

| **End point values** | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 551 | 662 | | |
| Units: mEq/L | | | | |
| least squares mean (confidence interval 95%) | -1 (-1.2 to -0.8) | -1.3 (-1.5 to -1.1) | | |

**Statistical analyses**

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1213 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.019 |
| Method | Constrained Longitudinal Data Analysis |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 0.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0 |
| upper limit | 0.5 |

**Primary: Change From Baseline in Chloride at Week 76-Base Study**

| End point title | Change From Baseline in Chloride at Week 76-Base Study |
|---|---|
| End point description: | |
| Chloride levels were assessed at baseline and after 76 weeks of treatment. The change from baseline was recorded. | |
| End point type | Primary |
| End point timeframe: | |
| Baseline and Week 76 | |

| **End point values** | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 551 | 662 | | |
| Units: mEq/L | | | | |
| least squares mean (confidence interval 95%) | -1.8 (-2 to -1.5) | -1.9 (-2.1 to -1.7) | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1213 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.414 |
| Method | Constrained Longitudinal Data Analysis |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 0.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.2 |
| upper limit | 0.4 |

## Primary: Change From Baseline in Bicarbonate at Week 76-Base Study

| End point title | Change From Baseline in Bicarbonate at Week 76-Base Study |
|---|---|
| End point description: | |
| Bicarbonate levels were assessed at baseline and after 76 weeks of treatment. The change from baseline was recorded. | |
| End point type | Primary |
| End point timeframe: | |
| Baseline and Week 76 | |

| End point values | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 552 | 664 | | |
| Units: mEq/L | | | | |
| least squares mean (confidence interval 95%) | 0.2 (0 to 0.4) | 0.3 (0.1 to 0.5) | | |

### Statistical analyses

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |

| | |
|---|---|
| Number of subjects included in analysis | 1216 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.791 |
| Method | Constrained Longitudinal Data Analysis |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.3 |
| upper limit | 0.2 |

## Primary: Change From Baseline in Potassium at Week 76-Base Study

| | |
|---|---|
| End point title | Change From Baseline in Potassium at Week 76-Base Study |
| End point description: | |
| Potassium levels were assessed at baseline and after 76 weeks of treatment. The change from baseline was recorded. | |
| End point type | Primary |
| End point timeframe: | |
| Baseline and Week 76 | |

| End point values | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 549 | 657 | | |
| Units: mEq/L | | | | |
| least squares mean (confidence interval 95%) | -0.1 (-0.1 to -0.1) | -0.1 (-0.1 to -0.1) | | |

## Statistical analyses

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1206 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.282 |
| Method | Constrained Longitudinal Data Analysis |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 0 |

| | |
|---|---|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.1 |
| upper limit | 0 |

## Primary: Percentage of Participants With Elevations in Systolic Blood Pressure (SBP) ≥ 10 mm Hg-Treatment Phase- Base Study

| | |
|---|---|
| End point title | Percentage of Participants With Elevations in Systolic Blood Pressure (SBP) ≥ 10 mm Hg-Treatment Phase- Base Study |

End point description:

Participants had SBP assessed at baseline and throughout the 76 week Treatment Phase. Participants who had a SBP reading that was ≥ 10 mm Hg higher than their baseline level for any assessment performed during the treatment period were recorded.

| | |
|---|---|
| End point type | Primary |

End point timeframe:

up to 76 weeks

| End point values | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 801 | 796 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 62.5 | 64.8 | | |

### Statistical analyses

| Statistical analysis title | Between Group comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1597 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.344 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | -2.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -7 |
| upper limit | 2.4 |

## Primary: Percentage of Participants With Elevations in SBP ≥ 15 mm Hg- Treatment Phase- Base Study

| | |
|---|---|
| End point title | Percentage of Participants With Elevations in SBP ≥ 15 mm Hg-Treatment Phase- Base Study |

End point description:

Participants had SBP assessed throughout the 76 week Treatment Phase. Participants who had a SBP reading that was ≥ 15 mm Hg higher than their baseline level for any assessment performed during the treatment period were recorded.

| | |
|---|---|
| End point type | Primary |

End point timeframe:

up to 76 weeks

| End point values | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 801 | 796 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 44.2 | 47.4 | | |

### Statistical analyses

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1597 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.204 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | -3.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -8 |
| upper limit | 1.7 |

## Primary: Percentage of Participants With Elevations in Diastolic Blood Pressure (DBP) ≥ 10 mm Hg-Treatment Phase- Base Study

| | |
|---|---|
| End point title | Percentage of Participants With Elevations in Diastolic Blood Pressure (DBP) ≥ 10 mm Hg-Treatment Phase- Base Study |

End point description:

Participants had DBP assessed throughout the 76 week Treatment Phase. Participants who had a DBP reading that was ≥ 10 mm Hg higher than their baseline level for any assessment performed during the treatment period were recorded.

| | |
|---|---|
| End point type | Primary |

End point timeframe:

up to 76 weeks

| End point values | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 801 | 796 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 40.4 | 39.9 | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1597 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.839 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Percentages |
| Point estimate | 0.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.3 |
| upper limit | 5.3 |

**Primary: Change From Baseline in SBP at Week 76-Base Study**

| End point title | Change From Baseline in SBP at Week 76-Base Study |
|---|---|
| End point description: | |
| Participants had SBP measured at baseline and after 76 weeks of treatment. The change from baseline was recorded. | |
| End point type | Primary |
| End point timeframe: | |
| Baseline and Week 76 | |

| End point values | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 551 | 665 | | |
| Units: mmHg | | | | |
| least squares mean (confidence interval 95%) | 2.2 (1 to 3.3) | 2.1 (1 to 3.1) | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1216 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.896 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 0.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.4 |
| upper limit | 1.6 |

**Primary: Change From Baseline in DBP at Week 76-Base Study**

| End point title | Change From Baseline in DBP at Week 76-Base Study |
|---|---|
| End point description: | |
| Participants had DBP measured at baseline and after 76 weeks of treatment. The change from baseline was recorded. | |
| End point type | Primary |
| End point timeframe: | |
| Baseline and Week 76 | |

| End point values | Anacetrapib 100 mg - Base Study - Safety | Placebo - Base Study- Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 551 | 665 | | |
| Units: mmHg | | | | |
| least squares mean (confidence interval 95%) | 0.7 (0 to 1.3) | 0.7 (0.1 to 1.3) | | |

**Statistical analyses**

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study - Safety v Placebo - Base Study- Safety |
| Number of subjects included in analysis | 1216 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.87 |
| Method | Miettinen and Nurminen |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | -0.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.9 |
| upper limit | 0.8 |

**Primary: Change from Baseline in Sodium at Week 104-Extension Study**

| End point title | Change from Baseline in Sodium at Week 104-Extension Study |
|---|---|
| End point description: | |
| Sodium levels were assessed at baseline and after 104 weeks of treatment. The change from baseline was recorded. | |
| End point type | Primary |
| End point timeframe: | |
| Baseline and Week 104 | |

| **End point values** | Anacetrapib 100 mg - Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 308 | 359 | | |
| Units: mEq/L | | | | |
| least squares mean (confidence interval 95%) | -0.3 (-0.5 to -0.1) | -0.3 (-0.5 to -0.1) | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 667 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.2 |
| upper limit | 0.3 |

**Primary: Change From Baseline in Chloride at Week 104-Extension Study**

| End point title | Change From Baseline in Chloride at Week 104-Extension Study |
|---|---|
| End point description: | |
| Chloride levels were assessed at baseline and after 104 weeks of treatment. The change from baseline was recorded. | |
| End point type | Primary |
| End point timeframe: | |
| Baseline and Week 104 | |

| End point values | Anacetrapib 100 mg -Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 308 | 359 | | |
| Units: mEq/L | | | | |
| least squares mean (confidence interval 95%) | -1.9 (-2.2 to -1.6) | -2.1 (-2.4 to -1.8) | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 667 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 0.1 |

| | |
|---|---|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.2 |
| upper limit | 0.5 |

## Primary: Change From Baseline in Bicarbonate at Week 104-Extension Study

| | |
|---|---|
| End point title | Change From Baseline in Bicarbonate at Week 104-Extension Study |

End point description:

Bicarbonate levels were assessed at baseline and after 104 weeks of treatment. The change from baseline was recorded.

| | |
|---|---|
| End point type | Primary |

End point timeframe:

Baseline and Week 104

| End point values | Anacetrapib 100 mg -Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 308 | 359 | | |
| Units: mEq/L | | | | |
| least squares mean (confidence interval 95%) | 0.2 (0 to 0.5) | 0.2 (0 to 0.5) | | |

### Statistical analyses

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 667 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.3 |
| upper limit | 0.4 |

## Primary: Change From Baseline in Potassium at Week 104-Extension Study

| End point title | Change From Baseline in Potassium at Week 104-Extension Study |
|---|---|

End point description:

Potassium levels were assessed at baseline and after 104 weeks of treatment. The change from baseline was recorded.

| End point type | Primary |
|---|---|

End point timeframe:

Baseline and Week 104

| **End point values** | Anacetrapib 100 mg -Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 308 | 359 | | |
| Units: mEq/L | | | | |
| least squares mean (confidence interval 95%) | 0 (-0.1 to 0) | -0.1 (-0.1 to -0.1) | | |

**Statistical analyses**

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 667 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 0.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0 |
| upper limit | 0.1 |

## Primary: Percentage of Participants With Elevations in SBP ≥ 10 mmHg-Extension Study

| End point title | Percentage of Participants With Elevations in SBP ≥ 10 mmHg-Extension Study |
|---|---|

End point description:

Participants had SBP assessed at baseline and throughout the 104 week Extension Study. Participants who had a SBP reading that was ≥ 10 mm Hg higher than their baseline level for any assessment performed during the treatment period were recorded.

| End point type | Primary |
|---|---|

End point timeframe:

up to 104 weeks

| End point values | Anacetrapib 100 mg - Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 366 | 432 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 63.9 | 59.7 | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 798 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Percentages |
| Point estimate | 4.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.6 |
| upper limit | 10.9 |

**Primary: Percentage of Participants With Elevations in SBP ≥ 15mm Hg-Extension Study**

| End point title | Percentage of Participants With Elevations in SBP ≥ 15mm Hg-Extension Study |
|---|---|
| End point description: | |
| Participants had SBP assessed at baseline and throughout the 104 week Extension Study. Participants who had a SBP reading that was ≥ 15 mm Hg higher than their baseline level for any assessment performed during the treatment period were recorded. | |
| End point type | Primary |
| End point timeframe: | |
| up to 104 weeks | |

| End point values | Anacetrapib 100 mg - Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 366 | 432 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 49.7 | 45.8 | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 798 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Percentages |
| Point estimate | 3.9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.1 |
| upper limit | 10.8 |

**Primary: Percentage of Participants With Elevations in DBP ≥ 10 mm Hg-Extension Study**

| End point title | Percentage of Participants With Elevations in DBP ≥ 10 mm Hg-Extension Study |
|---|---|
| End point description: | |
| Participants had DBP assessed at baseline and throughout the 104 week Extension Study. Participants who had a DBP reading that was ≥ 10 mm Hg higher than their baseline level for any assessment performed during the treatment period were recorded. | |
| End point type | Primary |
| End point timeframe: | |
| up to 104 weeks | |

| End point values | Anacetrapib 100 mg - Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 366 | 432 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 38 | 33.8 | | |

**Statistical analyses**

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 798 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Percentages |
| Point estimate | 4.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.5 |
| upper limit | 10.9 |

| **Primary: Change From Baseline in SBP at Week 104-Extension Study** | |
|---|---|
| End point title | Change From Baseline in SBP at Week 104-Extension Study |
| End point description: | |
| Participants had SBP measured at baseline and after 104 weeks of treatment. The change from baseline was recorded. | |
| End point type | Primary |
| End point timeframe: | |
| Baseline and Week 104 | |

| **End point values** | Anacetrapib 100 mg -Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 313 | 361 | | |
| Units: mmHg | | | | |
| least squares mean (confidence interval 95%) | 2.8 (1.2 to 44) | 2.1 (0.6 to 3.6) | | |

**Statistical analyses**

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |

| | |
|---|---|
| Number of subjects included in analysis | 674 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 0.7 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.4 |
| upper limit | 2.7 |

## Primary: Change From Baseline in DBP at Week 104-Extension Study

| | |
|---|---|
| End point title | Change From Baseline in DBP at Week 104-Extension Study |
| End point description: | |
| Participants had DBP measured at baseline and after 104 weeks of treatment. The change from baseline was recorded. | |
| End point type | Primary |
| End point timeframe: | |
| Baseline and Week 104 | |

| **End point values** | Anacetrapib 100 mg -Extension-Safety | Placebo-Extension Study-Safety | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 313 | 361 | | |
| Units: mmHg | | | | |
| least squares mean (confidence interval 95%) | -0.1 (-1 to 0.9) | -0.9 (-1.8 to -0.1) | | |

### Statistical analyses

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg -Extension-Safety v Placebo-Extension Study-Safety |
| Number of subjects included in analysis | 674 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 0.9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.3 |
| upper limit | 2.1 |

## Secondary: Percentage Change from Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 24- Base Study

| | |
|---|---|
| End point title | Percentage Change from Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 24- Base Study |
| End point description: | |
| HDL-C levels measured at baseline and after 24 weeks of treatment. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Week 24 | |

| **End point values** | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 685 | 744 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | 153 (149.9 to 156.2) | 14.6 (11.6 to 17.7) | | |

### Statistical analyses

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |
| Number of subjects included in analysis | 1429 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.001 |
| Method | Constrained Longitudinal Data Analysis |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 138.4 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 134.2 |
| upper limit | 142.6 |

## Secondary: Percentage Change from Baseline in Non-High Density Lipoprotein Cholesterol at Week 24- Base Study

| | |
|---|---|
| End point title | Percentage Change from Baseline in Non-High Density Lipoprotein Cholesterol at Week 24- Base Study |

| | |
|---|---|
| End point description: | |
| Non-HDL-C measured at baseline and after 24 weeks of treatment. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Week 24 | |

| **End point values** | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 685 | 744 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | -36.1 (-37.5 to -34.7) | -4.1 (-5.5 to -2.8) | | |

**Statistical analyses**

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |
| Number of subjects included in analysis | 1429 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.001 |
| Method | Constrained Longitudinal Data Analysis |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | -31.9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -33.8 |
| upper limit | -30 |

**Secondary: Percentage Change from Baseline in Apolipoprotein B at Week 24- Base Study**

| End point title | Percentage Change from Baseline in Apolipoprotein B at Week 24- Base Study |
|---|---|
| End point description: | |
| Apolipoprotein B was measured at baseline and after 24 weeks of treatment. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Week 24 | |

| End point values | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 769 | 767 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | -19.1 (-20.4 to -17.8) | 2 (0.7 to 3.3) | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |
| Number of subjects included in analysis | 1536 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.001 |
| Method | Constrained Longitudinal Data Analysis |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | -21.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -22.8 |
| upper limit | -19.4 |

**Secondary: Percentage Change from Baseline in Apolipoprotein A-1 at Week 24- Base Study**

| End point title | Percentage Change from Baseline in Apolipoprotein A-1 at Week 24- Base Study |
|---|---|
| End point description: | |
| Apolipoprotein A-1 measured at baseline and after 24 weeks of treatment. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Week 24 | |

| End point values | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 769 | 767 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | 47.5 (46.1 to 48.9) | 2.8 (1.4 to 4.2) | | |

**Statistical analyses**

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |
| Number of subjects included in analysis | 1536 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.001 |
| Method | Constrained Longitudinal Data Analysis |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 44.7 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 42.8 |
| upper limit | 46.6 |

**Secondary: Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 76- Base Study**

| End point title | Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 76- Base Study |
|---|---|
| End point description: | |
| LDL-C levels measured at baseline and after 76 weeks of treatment measured by Friedewald method | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Week 76 | |

| **End point values** | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 543 | 665 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | -40.5 (-42.5 to -38.6) | -4.4 (-6.2 to -2.6) | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |
| Number of subjects included in analysis | 1208 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.001 |
| Method | Constrained Longitudinal Data Analysis; |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | -36.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -38.7 |
| upper limit | -33.5 |

## Secondary: Percentage Change from Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 76- Base Study

| End point title | Percentage Change from Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 76- Base Study |
|---|---|
| End point description: | |
| HDL-C measured at baseline and after 76 week of treatment. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Week 76 | |

| End point values | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 548 | 666 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | 151.2 (148 to 154.3) | 12.2 (9.2 to 15.3) | | |

### Statistical analyses

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |

| | |
|---|---|
| Number of subjects included in analysis | 1214 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.001 |
| Method | Constrained Longitudinal Data Analysis |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 138.9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 134.7 |
| upper limit | 143.2 |

## Secondary: Percentage Change from Baseline in Non-high Density Lipoprotein Cholesterol at Week 76- Base Study

| | |
|---|---|
| End point title | Percentage Change from Baseline in Non-high Density Lipoprotein Cholesterol at Week 76- Base Study |
| End point description: | |
| Non-HDL-C measured at baseline and after 76 week of treatment. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Week 76 | |

| **End point values** | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 548 | 666 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | -33.1 (-34.8 to -31.5) | -3.8 (-5.3 to -2.2) | | |

### Statistical analyses

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |
| Number of subjects included in analysis | 1214 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.001 |
| Method | Constrained Longitudinal Data Analysis |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | -29.3 |

| | |
|---|---|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -31.5 |
| upper limit | -27.1 |

## Secondary: Percentage Change from Baseline in Apolipoprotein B at Week 76- Base Study

| | |
|---|---|
| End point title | Percentage Change from Baseline in Apolipoprotein B at Week 76- Base Study |
| End point description: | |
| Apolipoprotein B measured at baseline and after 76 weeks of treatment. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Week 76 | |

| End point values | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 572 | 670 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | -20.6 (-22.1 to -19.1) | -2.3 (-3.7 to -0.9) | | |

### Statistical analyses

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |
| Number of subjects included in analysis | 1242 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.001 |
| Method | Constrained Longitudinal Data Analysis |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | -18.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -20.2 |
| upper limit | -16.4 |

## Secondary: Percentage Change from Baseline in Apolipoprotein A-1 at Week 76- Base Study

| End point title | Percentage Change from Baseline in Apolipoprotein A-1 at Week 76- Base Study |
|---|---|

End point description:

Apolipoprotein A-1 measured at baseline and after 76 weeks of treatment.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline and Week 76

| End point values | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 572 | 670 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | 41.8 (40.4 to 43.2) | -0.5 (-1.8 to 0.9) | | |

### Statistical analyses

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |
| Number of subjects included in analysis | 1242 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.001 |
| Method | Constrained Longitudinal Data Analysis |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 42.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 40.4 |
| upper limit | 44.1 |

## Secondary: Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 88- Base Study

| End point title | Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 88- Base Study |
|---|---|

End point description:

LDL-C measured at baseline and at Week 88 (76 weeks treatment then 12 week reversal [no treatment])

| End point type | Secondary |
|---|---|

| |
|---|
| End point timeframe:<br>Baseline and Week 88 |

| **End point values** | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 641 | 681 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | -24.5 (-26.6 to -22.4) | -5.9 (-7.9 to -3.9) | | |

**Statistical analyses**

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |
| Number of subjects included in analysis | 1322 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | -18.6 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -21.5 |
| upper limit | -15.7 |

**Secondary: Percentage Change from Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 88- Base Study**

| End point title | Percentage Change from Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 88- Base Study |
|---|---|
| End point description:<br>HDL-C measured at baseline and at Week 88 (76 weeks treatment then 12 week reversal [no treatment]) | |
| End point type | Secondary |
| End point timeframe:<br>Baseline and Week 88 | |

| End point values | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 655 | 685 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | 87.1 (84.6 to 89.7) | 14.1 (11.6 to 16.6) | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |
| Number of subjects included in analysis | 1340 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 73 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 69.4 |
| upper limit | 76.6 |

**Secondary: Percentage Change from Baseline in Non-High Density Lipoprotein Cholesterol at Week 88- Base Study**

| End point title | Percentage Change from Baseline in Non-High Density Lipoprotein Cholesterol at Week 88- Base Study |
|---|---|
| End point description: | |
| Non-HDL-C measured at baseline and at Week 88 (76 weeks treatment then 12 week reversal [no treatment]) | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Week 88 | |

| End point values | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 655 | 685 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | -21.8 (-23.6 to -20) | -4.2 (-6 to -2.5) | | |

**Statistical analyses**

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |
| Number of subjects included in analysis | 1340 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | -17.6 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -20 |
| upper limit | -15.1 |

**Secondary: Percentage Change from Baseline in Apolipoprotein B at Week 88- Base Study**

| End point title | Percentage Change from Baseline in Apolipoprotein B at Week 88- Base Study |
|---|---|
| End point description: | |
| Apolipoprotein B measured at baseline and at Week 88 (76 weeks treatment then 12 week reversal [no treatment]) | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Week 88 | |

| **End point values** | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 651 | 677 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | -14.9 (-16.4 to -13.4) | -4.7 (-6.2 to -3.2) | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |
| Number of subjects included in analysis | 1328 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | -10.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -12.3 |
| upper limit | -8.1 |

**Secondary: Percentage Change from Baseline in Apolipoprotein A-1 at Week 88- Base Study**

| End point title | Percentage Change from Baseline in Apolipoprotein A-1 at Week 88- Base Study |
|---|---|
| End point description: | |
| Apolipoprotein A-1 measured at baseline and at Week 88 (76 weeks treatment then 12 week reversal [no treatment]) | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Week 88 | |

| End point values | Anacetrapib 100 mg - Base Study- Efficacy | Placebo - Base Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 651 | 677 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | 21.7 (20.6 to 22.9) | -2.8 (-3.9 to -1.6) | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Base Study- Efficacy v Placebo - Base Study - Efficacy |
| Number of subjects included in analysis | 1328 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 24.5 |

| | |
|---|---|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 22.9 |
| upper limit | 26.1 |

## Secondary: Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 104- Extension Study

| | |
|---|---|
| End point title | Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 104- Extension Study |
| End point description: | |
| LDL-C levels measured at baseline and after 104 weeks of treatment measured by Friedewald method | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Week 104 of Extension Study | |

| **End point values** | Anacetrapib 100 mg - Extension Study - Efficacy | Placebo- Extension Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 308 | 361 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | -45.2 (-48.2 to -42.3) | -5.4 (-8.1 to -2.6) | | |

### Statistical analyses

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Extension Study - Efficacy v Placebo- Extension Study - Efficacy |
| Number of subjects included in analysis | 669 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | -39.9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -43.8 |
| upper limit | -36 |

## Secondary: Percentage Change from Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 104- Extension Study

| | |
|---|---|
| End point title | Percentage Change from Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 104- Extension Study |
| End point description: HDL-C levels measured at baseline and after 104 weeks of treatment. | |
| End point type | Secondary |
| End point timeframe: Baseline and week 104 of Extension | |

| **End point values** | Anacetrapib 100 mg - Extension Study - Efficacy | Placebo- Extension Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 310 | 361 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | 169.3 (165 to 173.7) | 15.8 (11.7 to 19.8) | | |

### Statistical analyses

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Extension Study - Efficacy v Placebo- Extension Study - Efficacy |
| Number of subjects included in analysis | 671 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 153.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 147.9 |
| upper limit | 159.2 |

## Secondary: Percentage Change from Baseline in Non-High Density Lipoprotein Cholesterol at Week 104- Extension Study

| | |
|---|---|
| End point title | Percentage Change from Baseline in Non-High Density Lipoprotein Cholesterol at Week 104- Extension Study |
| End point description: Non-HDL-C levels measured at baseline and after 104 weeks of treatment. | |
| End point type | Secondary |
| End point timeframe: Baseline and Week 104 of Extension Study | |

| End point values | Anacetrapib 100 mg - Extension Study - Efficacy | Placebo-Extension Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 310 | 361 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | -35.5 (-38.1 to -33) | -4.6 (-7 to -2.3) | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Extension Study - Efficacy v Placebo-Extension Study - Efficacy |
| Number of subjects included in analysis | 671 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares means |
| Point estimate | -30.9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -34.2 |
| upper limit | -27.5 |

**Secondary: Percentage Change from Baseline in Apolipoprotein B at Week 104-Extension Study**

| End point title | Percentage Change from Baseline in Apolipoprotein B at Week 104- Extension Study |
|---|---|
| End point description: | |
| Apolipoprotein B levels measured at baseline and after 104 weeks of treatment. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Week 104 of Extension Study | |

| End point values | Anacetrapib 100 mg - Extension Study - Efficacy | Placebo- Extension Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 310 | 358 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | -30.6 (-32.6 to -28.6) | -14.3 (-16.2 to -12.4) | | |

**Statistical analyses**

| Statistical analysis title | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Extension Study - Efficacy v Placebo- Extension Study - Efficacy |
| Number of subjects included in analysis | 668 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | -16.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -18.9 |
| upper limit | -13.7 |

**Secondary: Percentage Change from Baseline in Apolipoprotein A-1 at Week 104- Extension Study**

| End point title | Percentage Change from Baseline in Apolipoprotein A-1 at Week 104- Extension Study |
|---|---|
| End point description: | |
| Apolipoprotein A-1 levels measured at baseline and after 104 weeks of treatment. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline and Week 104 of Extension Study | |

| End point values | Anacetrapib 100 mg - Extension Study - Efficacy | Placebo- Extension Study - Efficacy | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 310 | 358 | | |
| Units: Percentage Change | | | | |
| least squares mean (confidence interval 95%) | 41.8 (39.5 to 44.1) | -2.7 (-4.8 to -0.5) | | |

**Statistical analyses**

| **Statistical analysis title** | Between Group Comparison |
|---|---|
| Comparison groups | Anacetrapib 100 mg - Extension Study - Efficacy v Placebo-Extension Study - Efficacy |
| Number of subjects included in analysis | 668 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Difference in Least-squares Means |
| Point estimate | 44.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 41.6 |
| upper limit | 47.4 |

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Base Study-Treatment Phase-up to 76 weeks; Reversal Phase-up to 12 weeks; Post-study Phase- up to 24 weeks. Extension Study-up to 104 weeks. Reversal Study-up to 52 weeks

Adverse event reporting additional description:

AE additional description

| | |
|---|---|
| Assessment type | Systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 15.0 |

### Reporting groups

| | |
|---|---|
| Reporting group title | Placebo-Treatment Phase-Base Study |

Reporting group description:

Participants who received at least 1 dose of placebo in Treatment Phase of Base Study and had available safety data.

| | |
|---|---|
| Reporting group title | Placebo-Reversal Phase-Base Study |

Reporting group description:

Participants, who received at least 1 dose of Placebo in Treatment Phase of Base Study, started Reversal Phase of Base Study and had available safety data.

| | |
|---|---|
| Reporting group title | Anacetrapib 100 mg-Treatment Phase-Base Study |

Reporting group description:

Participants who received at least 1 dose of Anacetrapib in Treatment Phase of Base Study and had available safety data.

| | |
|---|---|
| Reporting group title | Anacetrapid 100 mg-Reversal Phase-Base Study |

Reporting group description:

-Participants, who received at least 1 dose of Anacetrapib in Treatment Phase of Base Study, started Reversal Phase of Base Study and had available safety data.

| | |
|---|---|
| Reporting group title | Anacetrapib 100 mg-Post Treatment Phase-Base Study |

Reporting group description:

Participant enrolled in Base Study who received at least 1 dose of Anacetrapib in Treatment Phase of Base Study and had available safety data. Post Treatment period was period from end of Reversal Phase up to start of 2–year extension.

| | |
|---|---|
| Reporting group title | Anacetrapib-2-year Extension Study |

Reporting group description:

Participants who were enrolled in 2-year extension, received at least 1 dose of Anacetrapib and had available safety data.

| | |
|---|---|
| Reporting group title | Placebo-Post Treatment Phase-Base Study |

Reporting group description:

Participant enrolled in Base Study who received at least 1 dose of Placebo in Treatment Phase of Base Study and had available safety data. Post Treatment period was period from end of Reversal Phase up to start of 2–year extension.

| | |
|---|---|
| Reporting group title | Placebo-2-year Extension Study |

Reporting group description:

Participants who were enrolled in 2-year extension, received at least 1 dose of placebo and had available safety data.

| | |
|---|---|
| Reporting group title | Anacetrapib-1-year Reversal Study |

Reporting group description:

Participants who were enrolled in 1-year reversal, received at least 1 dose of Anacetrapib in the extension and had available safety data.

| | |
|---|---|
| Reporting group title | Placebo-1-year Reversal Study |

Reporting group description:

Participants who were enrolled in 1-year reversal, received at least 1 dose of Placebo in the extension

| **Serious adverse events** | Placebo-Treatment Phase-Base Study | Placebo-Reversal Phase-Base Study | Anacetrapib 100 mg-Treatment Phase-Base Study |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 118 / 804 (14.68%) | 19 / 714 (2.66%) | 112 / 808 (13.86%) |
| number of deaths (all causes) | 7 | 1 | 6 |
| number of deaths resulting from adverse events | 0 | 0 | 1 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Adenocarcinoma | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Benign gastric neoplasm | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder cancer | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder neoplasm | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder transitional cell carcinoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Brain neoplasm | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Breast cancer | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carcinoid tumour | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colon cancer | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal tract adenoma | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lip neoplasm malignant stage unspecified | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung neoplasm malignant | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Malignant melanoma | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to lung | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic neoplasm | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Metastatic renal cell carcinoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ovarian neoplasm | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatic carcinoma | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer | | | |
| subjects affected / exposed | 4 / 804 (0.50%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer stage II | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cell carcinoma stage III | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Squamous cell carcinoma | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 804 (0.12%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Squamous cell carcinoma of skin | | | |
| subjects affected / exposed | 2 / 804 (0.25%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thyroid neoplasm | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic lymphocytic leukaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-Hodgkin's lymphoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 2 / 804 (0.25%) | 0 / 714 (0.00%) | 3 / 808 (0.37%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung adenocarcinoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bowen's disease | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic squamous cell carcinoma | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Throat cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastric cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intraocular melanoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung adenocarcinoma metastatic | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lymphoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to bone | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to liver | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ovarian adenoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cell carcinoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectosigmoid cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thyroid cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leiomyosarcoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-small cell lung cancer | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer stage IV | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Glioblastoma multiforme | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Aortic aneurysm | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 2 / 808 (0.25%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aortic dissection | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arterial stenosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femoral artery aneurysm | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 714 (0.14%) | 2 / 808 (0.25%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intermittent claudication | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intra-abdominal haemorrhage | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral arterial occlusive disease | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery aneurysm | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral ischaemia | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Venous thrombosis limb | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral embolism | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aortic aneurysm rupture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arteriosclerosis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery stenosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombophlebitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertension | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Chest discomfort | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 1 / 714 (0.14%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chest pain | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 1 / 714 (0.14%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Death | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 5 / 804 (0.62%) | 1 / 714 (0.14%) | 6 / 808 (0.74%) |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 1 | 0 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sudden cardiac death | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Sudden death | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| Thrombosis in device | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Electrocution | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Allergy to arthropod sting | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anaphylactic shock | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Benign prostatic hyperplasia | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ovarian cyst | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostatism | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Uterine prolapse | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nasal septum deviation | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis chronic | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory distress | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |

| | | | |
|---|---|---|---|
| Depression | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Suicide attempt | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carotid bruit | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Ankle fracture | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 2 / 808 (0.25%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cervical vertebral fracture | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Concussion | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Facial bones fracture | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femur fracture | | | |
| subjects affected / exposed | 2 / 804 (0.25%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fibula fracture | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Incisional hernia | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Joint dislocation | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower limb fracture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meniscus lesion | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pelvic fracture | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Radius fracture | | | |
| subjects affected / exposed | 2 / 804 (0.25%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rib fracture | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin laceration | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Contusion | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Craniocerebral injury | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Head injury | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Heat stroke | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hip fracture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Humerus fracture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple fractures | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscle rupture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post-traumatic pain | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subdural haematoma | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tendon rupture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tibia fracture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thermal burn | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ulna fracture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| **Congenital, familial and genetic disorders** | | | |
| Hypertrophic cardiomyopathy | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| **Cardiac disorders** | | | |
| Acute coronary syndrome | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 6 / 804 (0.75%) | 0 / 714 (0.00%) | 2 / 808 (0.25%) |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Angina pectoris | | | |
| subjects affected / exposed | 11 / 804 (1.37%) | 1 / 714 (0.14%) | 5 / 808 (0.62%) |
| occurrences causally related to treatment / all | 0 / 11 | 0 / 1 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Angina unstable | | | |
| subjects affected / exposed | 3 / 804 (0.37%) | 0 / 714 (0.00%) | 3 / 808 (0.37%) |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aortic valve disease | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arteriosclerosis coronary artery | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial fibrillation | | | |
| subjects affected / exposed | 4 / 804 (0.50%) | 1 / 714 (0.14%) | 5 / 808 (0.62%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrioventricular block second degree | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac arrest | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Cardiac failure congestive | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 1 / 714 (0.14%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery disease | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 4 / 804 (0.50%) | 0 / 714 (0.00%) | 5 / 808 (0.62%) |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 0 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery occlusion | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery stenosis | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 3 / 804 (0.37%) | 0 / 714 (0.00%) | 4 / 808 (0.50%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| Myocardial ischaemia | | | |
| subjects affected / exposed | 3 / 804 (0.37%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Palpitations | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiomyopathy | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular fibrillation | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac failure | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrioventricular block complete | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac failure acute | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nodal rhythm | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Right ventricular failure | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ischaemic cardiomyopathy | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular tachycardia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Brain injury | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral arteriosclerosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral haematoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral infarction | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 2 / 808 (0.25%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 4 / 804 (0.50%) | 0 / 714 (0.00%) | 4 / 808 (0.50%) |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 0 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Multiple system atrophy | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Partial seizures | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peroneal nerve palsy | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Petit mal epilepsy | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post herpetic neuralgia | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 3 / 804 (0.37%) | 0 / 714 (0.00%) | 5 / 808 (0.62%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 8 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 2 / 804 (0.25%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vocal cord paralysis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Basal ganglia haemorrhage | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Amyotrophic lateral sclerosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lacunar infarction | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Convulsion | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombocytopenia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bone marrow oedema | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders | | | |
| Vertigo | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Anal fissure | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colonic polyp | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 3 / 804 (0.37%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulum intestinal haemorrhagic | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Food poisoning | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastritis | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorder | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematemesis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 2 / 804 (0.25%) | 0 / 714 (0.00%) | 3 / 808 (0.37%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal ischaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Melaena | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mesenteric vein thrombosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal perforation | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enteritis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis acute | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal symptom | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic gastroparesis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal necrosis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal vascular malformation | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal stenosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Umbilical hernia, obstructive | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulum | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia, obstructive | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestine perforation | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis acute | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gallbladder necrosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemobilia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Angioedema | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukocytoclastic vasculitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Scar pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute prerenal failure | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure acute | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal artery stenosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Calculus bladder | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephrotic syndrome | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Stress urinary incontinence | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Calculus ureteric | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Carcinoid syndrome | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Hyperparathyroidism | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 2 / 808 (0.25%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arthritis | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Back pain | | | |
| subjects affected / exposed | 2 / 804 (0.25%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Costochondritis | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc degeneration | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 2 / 804 (0.25%) | 0 / 714 (0.00%) | 2 / 808 (0.25%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lumbar spinal stenosis | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myositis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 2 / 804 (0.25%) | 0 / 714 (0.00%) | 4 / 808 (0.50%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal column stenosis | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal osteoarthritis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tendonitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 714 (0.14%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Exostosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteonecrosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rhabdomyolysis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 2 / 804 (0.25%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic sinusitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic foot infection | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulitis | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Erysipelas | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia infection | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 2 / 808 (0.25%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Groin abscess | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infected skin ulcer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Lobar pneumonia | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung infection | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malaria | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mastoiditis | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nasal abscess | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 2 / 804 (0.25%) | 1 / 714 (0.14%) | 3 / 808 (0.37%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post procedural infection | | | |
| subjects affected / exposed | 2 / 804 (0.25%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyelonephritis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 2 / 808 (0.25%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vestibular neuronitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Septic shock | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchopneumonia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Appendicitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colon gangrene | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Device related infection | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gangrene | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal bacteraemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Streptococcal sepsis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cystitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound infection | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 1 / 808 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obesity | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic ketoacidosis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Type 2 diabetes mellitus | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetes mellitus | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 714 (0.00%) | 0 / 808 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Anacetrapid 100 mg-Reversal Phase-Base Study | Anacetrapib 100 mg-Post Treatment Phase-Base Study | Anacetrapib-2-year Extension Study |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 21 / 684 (3.07%) | 34 / 808 (4.21%) | 88 / 369 (23.85%) |
| number of deaths (all causes) | 1 | 7 | 9 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Adenocarcinoma | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Benign gastric neoplasm | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder cancer | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder neoplasm | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder transitional cell carcinoma | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Brain neoplasm | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Breast cancer | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carcinoid tumour | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colon cancer | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal tract adenoma | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lip neoplasm malignant stage unspecified | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung neoplasm malignant | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant melanoma | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to lung | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic neoplasm | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic renal cell carcinoma | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ovarian neoplasm | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatic carcinoma | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer stage II | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cancer | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cell carcinoma stage III | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 2 / 369 (0.54%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Squamous cell carcinoma of skin | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 3 / 369 (0.81%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thyroid neoplasm | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic lymphocytic leukaemia | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-Hodgkin's lymphoma | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 3 / 369 (0.81%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung adenocarcinoma | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Bowen's disease | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic squamous cell carcinoma | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Throat cancer | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastric cancer | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intraocular melanoma | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung adenocarcinoma metastatic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lymphoma | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to bone | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to liver | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ovarian adenoma | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal cancer | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cell carcinoma | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectosigmoid cancer | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thyroid cancer | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leiomyosarcoma | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-small cell lung cancer | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer stage IV | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Glioblastoma multiforme | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Aortic aneurysm | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 2 / 369 (0.54%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aortic dissection | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arterial stenosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femoral artery aneurysm | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intermittent claudication | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intra-abdominal haemorrhage | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral arterial occlusive disease | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery aneurysm | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral ischaemia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Venous thrombosis limb | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral embolism | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aortic aneurysm rupture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arteriosclerosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery stenosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombophlebitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertension | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chest pain | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 2 / 369 (0.54%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Death | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 3 / 808 (0.37%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 4 / 369 (1.08%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sudden cardiac death | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Sudden death | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Thrombosis in device | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocution | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Allergy to arthropod sting | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anaphylactic shock | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Benign prostatic hyperplasia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ovarian cyst | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostatism | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Uterine prolapse | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| **Respiratory, thoracic and mediastinal disorders** | | | |
| Asthma | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 3 / 369 (0.81%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nasal septum deviation | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 2 / 808 (0.25%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |

| | | | |
|---|---|---|---|
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis chronic | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory distress | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Depression | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Suicide attempt | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |

| | | | |
|---|---|---|---|
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carotid bruit | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| **Injury, poisoning and procedural complications** | | | |
| Ankle fracture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cervical vertebral fracture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Concussion | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Facial bones fracture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femur fracture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fibula fracture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Incisional hernia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Joint dislocation | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower limb fracture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meniscus lesion | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pelvic fracture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Radius fracture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin laceration | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Contusion | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Craniocerebral injury | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Head injury | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Heat stroke | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hip fracture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Humerus fracture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple fractures | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscle rupture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post-traumatic pain | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subdural haematoma | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tendon rupture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tibia fracture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thermal burn | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ulna fracture | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Congenital, familial and genetic disorders | | | |
| Hypertrophic cardiomyopathy | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Acute coronary syndrome | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 6 / 369 (1.63%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Angina pectoris | | | |
| subjects affected / exposed | 2 / 684 (0.29%) | 2 / 808 (0.25%) | 6 / 369 (1.63%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 9 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Angina unstable | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aortic valve disease | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arteriosclerosis coronary artery | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 2 / 808 (0.25%) | 5 / 369 (1.36%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrioventricular block second degree | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac arrest | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac failure congestive | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 2 / 808 (0.25%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery disease | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery occlusion | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery stenosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 2 / 369 (0.54%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 1 / 808 (0.12%) | 2 / 369 (0.54%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial ischaemia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Palpitations | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiomyopathy | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular fibrillation | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac failure | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 2 / 808 (0.25%) | 2 / 369 (0.54%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Atrioventricular block complete | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac failure acute | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nodal rhythm | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Right ventricular failure | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ischaemic cardiomyopathy | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular tachycardia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Brain injury | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral arteriosclerosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral haematoma | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral infarction | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 2 / 808 (0.25%) | 2 / 369 (0.54%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Multiple system atrophy | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Partial seizures | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peroneal nerve palsy | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Petit mal epilepsy | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post herpetic neuralgia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Presyncope | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 2 / 369 (0.54%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 2 / 369 (0.54%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vocal cord paralysis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Basal ganglia haemorrhage | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Amyotrophic lateral sclerosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lacunar infarction | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Convulsion | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 2 / 369 (0.54%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bone marrow oedema | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders | | | |
| Vertigo | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |

| | | | |
|---|---|---|---|
| Cataract | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anal fissure | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colonic polyp | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulum intestinal haemorrhagic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Food poisoning | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastritis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 2 / 369 (0.54%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematemesis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal ischaemia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Melaena | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mesenteric vein thrombosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal perforation | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enteritis | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis acute | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal symptom | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic gastroparesis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal necrosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal vascular malformation | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal stenosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Umbilical hernia, obstructive | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulum | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia, obstructive | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestine perforation | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis acute | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gallbladder necrosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemobilia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Angioedema | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukocytoclastic vasculitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Scar pain | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute prerenal failure | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure acute | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal artery stenosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Calculus bladder | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephrotic syndrome | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Stress urinary incontinence | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Calculus ureteric | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Carcinoid syndrome | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperparathyroidism | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Costochondritis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc degeneration | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lumbar spinal stenosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myositis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 2 / 684 (0.29%) | 2 / 808 (0.25%) | 2 / 369 (0.54%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal column stenosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal osteoarthritis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tendonitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Exostosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteonecrosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rhabdomyolysis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic foot infection | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Erysipelas | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia infection | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Groin abscess | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infected skin ulcer | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lobar pneumonia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung infection | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malaria | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mastoiditis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nasal abscess | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post procedural infection | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyelonephritis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vestibular neuronitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral upper respiratory tract infection | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Septic shock | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 2 / 369 (0.54%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 2 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchopneumonia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Appendicitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colon gangrene | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Device related infection | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gangrene | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal bacteraemia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Streptococcal sepsis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cystitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound infection | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obesity | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 1 / 684 (0.15%) | 1 / 808 (0.12%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic ketoacidosis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 0 / 369 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Type 2 diabetes mellitus | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 2 / 369 (0.54%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetes mellitus | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 0 / 808 (0.00%) | 1 / 369 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Placebo-Post Treatment Phase-Base Study | Placebo-2-year Extension Study | Anacetrapib-1-year Reversal Study |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 24 / 804 (2.99%) | 90 / 433 (20.79%) | 35 / 271 (12.92%) |
| number of deaths (all causes) | 5 | 9 | 1 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Adenocarcinoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Benign gastric neoplasm | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 2 / 271 (0.74%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder neoplasm | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder transitional cell carcinoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Brain neoplasm | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Breast cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carcinoid tumour | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Colon cancer | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal tract adenoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lip neoplasm malignant stage unspecified | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung neoplasm malignant | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant melanoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 3 / 433 (0.69%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to lung | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic neoplasm | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic renal cell carcinoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ovarian neoplasm | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatic carcinoma | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Prostate cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 2 / 433 (0.46%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer stage II | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cell carcinoma stage III | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 1 / 433 (0.23%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Squamous cell carcinoma of skin | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thyroid neoplasm | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic lymphocytic leukaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-Hodgkin's lymphoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung adenocarcinoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bowen's disease | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic squamous cell carcinoma | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Throat cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastric cancer | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intraocular melanoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung adenocarcinoma metastatic | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lymphoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to bone | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to liver | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ovarian adenoma | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cell carcinoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectosigmoid cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thyroid cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leiomyosarcoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-small cell lung cancer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer stage IV | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Glioblastoma multiforme | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Aortic aneurysm | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aortic dissection | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arterial stenosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femoral artery aneurysm | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intermittent claudication | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intra-abdominal haemorrhage | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral arterial occlusive disease | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery aneurysm | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral ischaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Venous thrombosis limb | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral embolism | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aortic aneurysm rupture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arteriosclerosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery stenosis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 2 / 433 (0.46%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombophlebitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertension | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Chest discomfort | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chest pain | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Death | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 9 / 433 (2.08%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 9 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sudden cardiac death | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sudden death | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombosis in device | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocution | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Allergy to arthropod sting | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anaphylactic shock | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Benign prostatic hyperplasia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Ovarian cyst | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostatism | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Uterine prolapse | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| **Respiratory, thoracic and mediastinal disorders** | | | |
| Asthma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nasal septum deviation | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 2 / 433 (0.46%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis chronic | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory distress | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Depression | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Suicide attempt | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carotid bruit | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Ankle fracture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cervical vertebral fracture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Concussion | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Facial bones fracture | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femur fracture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fibula fracture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Incisional hernia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Joint dislocation | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower limb fracture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meniscus lesion | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pelvic fracture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Radius fracture | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin laceration | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Contusion | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Craniocerebral injury | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 2 / 433 (0.46%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Head injury | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Heat stroke | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Hip fracture | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Humerus fracture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple fractures | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscle rupture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post-traumatic pain | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subdural haematoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tendon rupture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tibia fracture | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thermal burn | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ulna fracture | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Congenital, familial and genetic disorders | | | |
| Hypertrophic cardiomyopathy | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Acute coronary syndrome | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 2 / 433 (0.46%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 3 / 433 (0.69%) | 3 / 271 (1.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Angina pectoris | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 5 / 433 (1.15%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 5 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Angina unstable | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 3 / 433 (0.69%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Aortic valve disease | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arteriosclerosis coronary artery | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial fibrillation | | | |
| subjects affected / exposed | 2 / 804 (0.25%) | 1 / 433 (0.23%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrioventricular block second degree | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac arrest | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac failure congestive | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery disease | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 2 / 433 (0.46%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery occlusion | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery stenosis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 2 / 433 (0.46%) | 2 / 271 (0.74%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial ischaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Palpitations | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiomyopathy | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular fibrillation | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac failure | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Atrioventricular block complete | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac failure acute | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nodal rhythm | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Right ventricular failure | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Ischaemic cardiomyopathy | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular tachycardia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Brain injury | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral arteriosclerosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral haematoma | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral infarction | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 4 / 433 (0.92%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple system atrophy | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Partial seizures | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peroneal nerve palsy | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Petit mal epilepsy | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post herpetic neuralgia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 3 / 433 (0.69%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vocal cord paralysis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Basal ganglia haemorrhage | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Amyotrophic lateral sclerosis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lacunar infarction | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Convulsion | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| **Blood and lymphatic system disorders** | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 2 / 433 (0.46%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bone marrow oedema | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders | | | |
| Vertigo | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anal fissure | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Colonic polyp | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulum intestinal haemorrhagic | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Food poisoning | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastritis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematemesis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal ischaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Melaena | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mesenteric vein thrombosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal perforation | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 2 / 433 (0.46%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enteritis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis acute | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal symptom | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic gastroparesis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal necrosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal vascular malformation | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal stenosis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Umbilical hernia, obstructive | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulum | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia, obstructive | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestine perforation | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis acute | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gallbladder necrosis | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholecystitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemobilia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Angioedema | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukocytoclastic vasculitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Scar pain | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |

| | | | |
|---|---|---|---|
| Acute prerenal failure | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure acute | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 2 / 433 (0.46%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal artery stenosis | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Calculus bladder | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephrotic syndrome | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Stress urinary incontinence | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Calculus ureteric | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Carcinoid syndrome | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperparathyroidism | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Costochondritis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Intervertebral disc degeneration | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lumbar spinal stenosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myositis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 2 / 433 (0.46%) | 2 / 271 (0.74%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal column stenosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal osteoarthritis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tendonitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 804 (0.12%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Exostosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteonecrosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rhabdomyolysis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic foot infection | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Erysipelas | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia infection | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 2 / 433 (0.46%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Groin abscess | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infected skin ulcer | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lobar pneumonia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 3 / 433 (0.69%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung infection | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malaria | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mastoiditis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nasal abscess | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 7 / 433 (1.62%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 8 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Post procedural infection | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyelonephritis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vestibular neuronitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Septic shock | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 2 / 433 (0.46%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Bronchopneumonia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Appendicitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colon gangrene | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Device related infection | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gangrene | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal bacteraemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Streptococcal sepsis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cystitis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound infection | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obesity | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic ketoacidosis | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 0 / 271 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Type 2 diabetes mellitus | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 804 (0.00%) | 1 / 433 (0.23%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetes mellitus | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 0 / 433 (0.00%) | 1 / 271 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Placebo-1-year Reversal Study | | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Adenocarcinoma | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Benign gastric neoplasm | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bladder cancer | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bladder neoplasm | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bladder transitional cell carcinoma | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | | |
|---|---|---|---|---|
| Brain neoplasm | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Breast cancer | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Carcinoid tumour | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Colon cancer | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastrointestinal tract adenoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lip neoplasm malignant stage unspecified | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lung neoplasm malignant | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Malignant melanoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metastases to lung | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metastatic neoplasm | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metastatic renal cell carcinoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ovarian neoplasm | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pancreatic carcinoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Prostate cancer | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Prostate cancer stage II | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Renal cancer | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Renal cell carcinoma stage III | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Squamous cell carcinoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Squamous cell carcinoma of skin | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Thyroid neoplasm | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Chronic lymphocytic leukaemia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Non-Hodgkin's lymphoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Basal cell carcinoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lung adenocarcinoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bowen's disease | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metastatic squamous cell carcinoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Throat cancer | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastric cancer | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Intraocular melanoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lung adenocarcinoma metastatic | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lymphoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metastases to bone | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metastases to central nervous system | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metastases to liver | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Neoplasm malignant | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ovarian adenoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rectal cancer | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Renal cell carcinoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rectosigmoid cancer | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Thyroid cancer | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Leiomyosarcoma | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Non-small cell lung cancer | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Prostate cancer stage IV | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Glioblastoma multiforme | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Vascular disorders | | | | |
| Aortic aneurysm | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Aortic dissection | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Arterial stenosis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Femoral artery aneurysm | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypotension | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Intermittent claudication | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Intra-abdominal haemorrhage | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peripheral arterial occlusive disease | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peripheral artery aneurysm | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peripheral ischaemia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Venous thrombosis limb | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peripheral embolism | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Aortic aneurysm rupture | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Arteriosclerosis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Deep vein thrombosis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peripheral artery stenosis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Thrombophlebitis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypertension | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| General disorders and administration site conditions | | | | |
| Chest discomfort | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Chest pain | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Death | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Non-cardiac chest pain | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Sudden cardiac death | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Sudden death | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Thrombosis in device | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Electrocution | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pyrexia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Immune system disorders | | | | |
| Allergy to arthropod sting | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypersensitivity | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Anaphylactic shock | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Reproductive system and breast disorders | | | | |
| Benign prostatic hyperplasia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ovarian cyst | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Prostatism | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Uterine prolapse | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Respiratory, thoracic and mediastinal disorders | | | | |
| Asthma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Dyspnoea | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |

| | | | | |
|---|---|---|---|---|
| Nasal septum deviation | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Oropharyngeal pain | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pulmonary embolism | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Chronic obstructive pulmonary disease | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Respiratory failure | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Acute respiratory failure | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bronchitis chronic | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Epistaxis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Respiratory distress | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Psychiatric disorders | | | |
| Depression | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Suicide attempt | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Investigations | | | |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Carotid bruit | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Injury, poisoning and procedural complications | | | |
| Ankle fracture | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cervical vertebral fracture | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Concussion | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Facial bones fracture | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Femur fracture | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Fibula fracture | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Incisional hernia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Joint dislocation | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lower limb fracture | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Meniscus lesion | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pelvic fracture | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Radius fracture | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rib fracture | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Skin laceration | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Contusion | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Craniocerebral injury | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Fall | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Head injury | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Heat stroke | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hip fracture | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Injury | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Humerus fracture | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Multiple fractures | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Muscle rupture | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Post-traumatic pain | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Subdural haematoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Tendon rupture | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Tibia fracture | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Thermal burn | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ulna fracture | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Congenital, familial and genetic disorders | | | | |
| Hypertrophic cardiomyopathy | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cardiac disorders | | | | |
| Acute coronary syndrome | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |

| | | | | |
|---|---|---|---|---|
| Acute myocardial infarction | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Angina pectoris | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Angina unstable | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Aortic valve disease | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Arteriosclerosis coronary artery | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Atrial fibrillation | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Atrioventricular block second degree | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cardiac arrest | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cardiac failure congestive | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Coronary artery disease | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Coronary artery occlusion | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Coronary artery stenosis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Myocardial infarction | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Myocardial ischaemia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Palpitations | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Sinus bradycardia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ventricular extrasystoles | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cardiomyopathy | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Supraventricular tachycardia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ventricular fibrillation | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bradycardia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cardiac failure | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Atrioventricular block complete | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cardiac failure acute | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nodal rhythm | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Right ventricular failure | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ischaemic cardiomyopathy | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ventricular tachycardia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nervous system disorders | | | | |
| Brain injury | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cerebral arteriosclerosis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cerebral haematoma | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cerebral infarction | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cerebrovascular accident | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Multiple system atrophy | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Partial seizures | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peroneal nerve palsy | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Petit mal epilepsy | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Post herpetic neuralgia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Presyncope | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Syncope | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Transient ischaemic attack | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Vocal cord paralysis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Basal ganglia haemorrhage | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Amyotrophic lateral sclerosis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Carpal tunnel syndrome | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cerebral haemorrhage | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lacunar infarction | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Convulsion | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Blood and lymphatic system disorders | | | | |
| Anaemia | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bone marrow oedema | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ear and labyrinth disorders | | | |
| Vertigo | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | | |
|---|---|---|---|---|
| Abdominal pain upper | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Anal fissure | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Colitis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Colonic polyp | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Constipation | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diarrhoea | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diverticulum intestinal haemorrhagic | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Food poisoning | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastritis | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastrointestinal disorder | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastrooesophageal reflux disease | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Haematemesis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Inguinal hernia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Intestinal ischaemia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Melaena | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Mesenteric vein thrombosis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nausea | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Oesophageal perforation | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Upper gastrointestinal haemorrhage | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Enteritis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastrointestinal haemorrhage | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pancreatitis acute | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Abdominal symptom | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diabetic gastroparesis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Dyspepsia | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastrointestinal necrosis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastrointestinal vascular malformation | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Oesophageal stenosis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pancreatitis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Umbilical hernia, obstructive | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diverticulum | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Inguinal hernia, obstructive | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Large intestine perforation | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatobiliary disorders | | | |
| Cholecystitis acute | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gallbladder necrosis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Haemobilia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatitis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Angioedema | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Leukocytoclastic vasculitis | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Scar pain | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Skin ulcer | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Renal and urinary disorders | | | | |
| Acute prerenal failure | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Renal failure acute | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Renal artery stenosis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Calculus bladder | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Haematuria | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nephrolithiasis | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Renal failure | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nephrotic syndrome | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Stress urinary incontinence | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Calculus ureteric | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Endocrine disorders | | | | |
| Carcinoid syndrome | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hyperparathyroidism | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Musculoskeletal and connective tissue disorders | | | | |
| Arthralgia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |

| | | | |
|---|---|---|---|
| Arthritis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Costochondritis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Intervertebral disc degeneration | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lumbar spinal stenosis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Myositis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Spinal column stenosis | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Spinal osteoarthritis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Musculoskeletal stiffness | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Tendonitis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Exostosis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Osteonecrosis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rhabdomyolysis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Infections and infestations | | | | |
| Bronchitis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cellulitis | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Chronic sinusitis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diabetic foot infection | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diverticulitis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Erysipelas | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Escherichia infection | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastroenteritis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Groin abscess | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Infected skin ulcer | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Influenza | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lobar pneumonia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lung infection | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Malaria | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Mastoiditis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nasal abscess | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pneumonia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Post procedural infection | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pyelonephritis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Upper respiratory tract infection | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Urinary tract infection | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Urosepsis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Vestibular neuronitis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Viral upper respiratory tract infection | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Herpes zoster | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Septic shock | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Sepsis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bronchopneumonia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Appendicitis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Colon gangrene | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Device related infection | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gangrene | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Staphylococcal bacteraemia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Streptococcal sepsis | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cystitis | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Wound infection | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metabolism and nutrition disorders | | | | |
| Dehydration | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hyperglycaemia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypoglycaemia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hyponatraemia | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Obesity | | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hyperkalaemia | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diabetic ketoacidosis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Type 2 diabetes mellitus | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diabetes mellitus | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | Placebo-Treatment Phase-Base Study | Placebo-Reversal Phase-Base Study | Anacetrapib 100 mg-Treatment Phase-Base Study |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 600 / 804 (74.63%) | 0 / 714 (0.00%) | 573 / 808 (70.92%) |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 60 / 804 (7.46%) | 0 / 714 (0.00%) | 47 / 808 (5.82%) |
| occurrences (all) | 77 | 0 | 54 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 33 / 804 (4.10%) | 0 / 714 (0.00%) | 45 / 808 (5.57%) |
| occurrences (all) | 36 | 0 | 48 |
| Musculoskeletal and connective tissue | | | |

| | | | |
|---|---|---|---|
| disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 37 / 804 (4.60%) | 0 / 714 (0.00%) | 46 / 808 (5.69%) |
| occurrences (all) | 54 | 0 | 52 |
| Back pain | | | |
| subjects affected / exposed | 36 / 804 (4.48%) | 0 / 714 (0.00%) | 42 / 808 (5.20%) |
| occurrences (all) | 40 | 0 | 46 |
| Pain in extremity | | | |
| subjects affected / exposed | 23 / 804 (2.86%) | 0 / 714 (0.00%) | 18 / 808 (2.23%) |
| occurrences (all) | 23 | 0 | 20 |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 44 / 804 (5.47%) | 0 / 714 (0.00%) | 36 / 808 (4.46%) |
| occurrences (all) | 47 | 0 | 38 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 82 / 804 (10.20%) | 0 / 714 (0.00%) | 87 / 808 (10.77%) |
| occurrences (all) | 102 | 0 | 129 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 63 / 804 (7.84%) | 0 / 714 (0.00%) | 47 / 808 (5.82%) |
| occurrences (all) | 76 | 0 | 54 |
| Metabolism and nutrition disorders | | | |
| Type 2 diabetes mellitus | | | |
| subjects affected / exposed | 25 / 804 (3.11%) | 0 / 714 (0.00%) | 16 / 808 (1.98%) |
| occurrences (all) | 27 | 0 | 16 |

| **Non-serious adverse events** | Anacetrapid 100 mg-Reversal Phase-Base Study | Anacetrapib 100 mg-Post Treatment Phase-Base Study | Anacetrapib-2-year Extension Study |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 158 / 808 (19.55%) | 269 / 369 (72.90%) |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 6 / 808 (0.74%) | 13 / 369 (3.52%) |
| occurrences (all) | 0 | 6 | 14 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 5 / 808 (0.62%) | 14 / 369 (3.79%) |
| occurrences (all) | 0 | 5 | 14 |
| Musculoskeletal and connective tissue | | | |

| | | | |
|---|---|---|---|
| disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 4 / 808 (0.50%) | 16 / 369 (4.34%) |
| occurrences (all) | 0 | 5 | 19 |
| Back pain | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 1 / 808 (0.12%) | 30 / 369 (8.13%) |
| occurrences (all) | 0 | 1 | 36 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 1 / 808 (0.12%) | 21 / 369 (5.69%) |
| occurrences (all) | 0 | 1 | 26 |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 3 / 808 (0.37%) | 23 / 369 (6.23%) |
| occurrences (all) | 0 | 3 | 25 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 12 / 808 (1.49%) | 31 / 369 (8.40%) |
| occurrences (all) | 0 | 13 | 39 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 6 / 808 (0.74%) | 18 / 369 (4.88%) |
| occurrences (all) | 0 | 6 | 28 |
| Metabolism and nutrition disorders | | | |
| Type 2 diabetes mellitus | | | |
| subjects affected / exposed | 0 / 684 (0.00%) | 4 / 808 (0.50%) | 8 / 369 (2.17%) |
| occurrences (all) | 0 | 4 | 9 |

| **Non-serious adverse events** | Placebo-Post Treatment Phase-Base Study | Placebo-2-year Extension Study | Anacetrapib-1-year Reversal Study |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 169 / 804 (21.02%) | 313 / 433 (72.29%) | 122 / 271 (45.02%) |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 3 / 804 (0.37%) | 17 / 433 (3.93%) | 3 / 271 (1.11%) |
| occurrences (all) | 3 | 24 | 3 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 0 / 804 (0.00%) | 19 / 433 (4.39%) | 5 / 271 (1.85%) |
| occurrences (all) | 0 | 21 | 5 |
| Musculoskeletal and connective tissue | | | |

| | | | |
|---|---|---|---|
| disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 6 / 804 (0.75%) | 25 / 433 (5.77%) | 3 / 271 (1.11%) |
| occurrences (all) | 6 | 26 | 3 |
| Back pain | | | |
| subjects affected / exposed | 8 / 804 (1.00%) | 28 / 433 (6.47%) | 3 / 271 (1.11%) |
| occurrences (all) | 8 | 29 | 3 |
| Pain in extremity | | | |
| subjects affected / exposed | 2 / 804 (0.25%) | 16 / 433 (3.70%) | 2 / 271 (0.74%) |
| occurrences (all) | 2 | 19 | 2 |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 1 / 804 (0.12%) | 11 / 433 (2.54%) | 4 / 271 (1.48%) |
| occurrences (all) | 1 | 13 | 4 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 6 / 804 (0.75%) | 34 / 433 (7.85%) | 17 / 271 (6.27%) |
| occurrences (all) | 6 | 39 | 20 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 8 / 804 (1.00%) | 32 / 433 (7.39%) | 4 / 271 (1.48%) |
| occurrences (all) | 8 | 43 | 4 |
| Metabolism and nutrition disorders | | | |
| Type 2 diabetes mellitus | | | |
| subjects affected / exposed | 4 / 804 (0.50%) | 23 / 433 (5.31%) | 2 / 271 (0.74%) |
| occurrences (all) | 4 | 24 | 2 |

| **Non-serious adverse events** | Placebo-1-year Reversal Study | | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | | |
| occurrences (all) | 0 | | |
| Musculoskeletal and connective tissue disorders | | | |

| | | | |
|---|---|---|---|
| Arthralgia<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | | |
| Back pain<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | | |
| Pain in extremity<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | | |
| Infections and infestations | | | |
| Bronchitis<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | | |
| Nasopharyngitis<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | | |
| Upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | | |
| Metabolism and nutrition disorders | | | |
| Type 2 diabetes mellitus<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | | |

## More information

## Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 11 June 2008 | AM1: Primary reason for the amendment was to revise the Participant Population to include only CHD/CHD risk-equivalent participants. |
| 20 March 2009 | AM2: Primary reason for the amendment was to add an interim safety analysis once all participants had reached Week 54. |
| 19 August 2009 | AM3: The primary reason for the amendment was to add the collection of safety follow-up information (serious cardiovascular adverse events or death) for discontinued participants at their intended Week 54 visit. |
| 22 February 2010 | AM4: The primary reason for this amendment was to extend the 12-week reversibility phase of Base Study by up to another 12 weeks (if required) in order to allow participants completing final visit (Week 88) to continue in the study until the planned extension study was ready for implementation at the site. |
| 17 March 2010 | Ext 10: The primary reason for this amendment was to add a 2-year Extension Study to the Base Study in order to further evaluate the long-term safety profile (~3.5years) and efficacy of anacetrapib in CHD/CHD-risk equivalent participants who were on ongoing therapy with a statin ± other lipid-modifying therapy. |
| 07 March 2011 | AM11 (AM1 to Ext10): The primary reason for this amendment was to add the results from the warfarin and digoxin drug interaction studies that was recently added to the Investigator's Brochure. As a result, digoxin or other cardiac glycosides and Coumadin (warfarin) or coumadin-like anticoagalants were no longer prohibited medications for the study. Added blood draws to estimate the time to steady state levels for anacetrapib. Also added an archive blood sample for biomarkers. |
| 13 January 2012 | AM12 (AM2 to Ext 10): The primary reason for this amendment was to extend the reversal period of the 2-year extension study from 12 weeks to 1-year. |
| 24 April 2013 | AM6: The primary reason for this amendment was to add a follow-up of 5 months up to 5 years for evaluation of pharmacokinetics and lipids for all participants who were previously treated with anacetrapib in the Base or Extension Studies (completed or discontinued). Additionally All women of child-bearing potential (WOCBP), who had previously received anacetrapib in the treatment phase would be contacted annually by the site for pregnancy and outcome. WOCBP would also receive guidance for proper use of contraception. |
| 02 June 2013 | AM14 (AM4 to Ext): The primary reason for this amendment was to reconcile the unblinding text such that participants can be unblinded after they complete the 2-year Extension Study on a rolling basis and then enrolled in AM6. |
| 17 October 2013 | AM7: The primary reason for the amendment was to add evaluations of participants to determine if anacetrapib levels were present in the adipose tissue, approximately 1 up to 5 years after the participant last took anacetrapib. |

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported